A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) (NCT06422923)
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Temporal Lobe Epilepsy (MTLE)
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
Who can join: Review the eligibility criteria below.
Location: University of Arkansas for Medical Sciences — Little Rock, Arkansas
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- University of Southern California Keck Hospital — Los Angeles, California
- UC Irvine Medical Center — Orange, California
- Stanford University — Palo Alto, California
- University of California San Diego — San Diego, California
- University of California San Francisco — San Francisco, California
- University of Colorado Anschutz Medical Campus — Aurora, Colorado
- University of Chicago — Chicago, Illinois
- University of Iowa Health Care — Iowa City, Iowa
- SUNY Upstate Medical University — Syracuse, New York
- Atrium Health — Charlotte, North Carolina
- Duke University Hospital — Durham, North Carolina
- Wake Forest Baptist Medical Center — Winston-Salem, North Carolina
- Oregon Health and Science University — Portland, Oregon
- UTHealth Houston — Houston, Texas
- UVA Health University Medical Center — Charlottesville, Virginia
- Medical College of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (650) 580-3825
Email: neuronamedinfo@neuronatx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Epilepsy, Temporal Lobe
- Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy — Edmonton, Alberta
Explore by condition: All Epilepsy, Temporal Lobe clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.